Adapalene/Clindamycin Gel in Vietnamese Acne Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 4, open-label, multicenter, prospective study in Vietnam evaluating adapalene 0.1%/clindamycin 1% gel used as part of standard practice. About 360 participants will apply the gel once daily for 12 weeks, with visits at baseline and Weeks 2, 4, 8, and 12. The main focus is safety and tolerability, including local skin reactions, with additional observations on changes in inflammatory and non-inflammatory lesions. The study describes real-world use of the product and its clinical effectiveness in routine dermatology care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients aged 12 years or more, of either gender diagnosed with acne vulgaris defined by:

   1. 10 to 50 inflammatory lesions (papules, pustules, and nodules)
   2. 5 to 50 non-inflammatory lesions (open and closed comedones)
   3. IGA score of mild (2) or moderate (3)
2. Patients who will refrain from use of any other topical medications, medicated cleansers, medicated moisturizers, or skincare products containing active ingredients such as azelaic acid, salicylic acid, niacinamide, glycolic acid, benzoyl peroxide, ethanol, resorcinol, alpha-hydroxy acids (AHAs), tretinoin, retinol, isotretinoin, ingredients derived from lime, menthol, camphor, citrus oils, nor have excessive exposure to sunlight throughout the study period.
3. Literate patients willing to give consent to participate in the study.

Exclusion Criteria:

1. Severe systemic disease as assessed by the Investigator that might interfere with the conduct of the study or the interpretation of the results.
2. Patients with concomitant facial dermatoses (e.g., Atopic dermatitis, Rosacea, Discoid lupus erythematosus, Sensitive skin syndrome, Irritant contact dermatitis, etc.)
3. Sunburn on the face.
4. Pregnant and lactating females.
5. Concurrent participation in another clinical study or use of other topical medications.
6. Refusal to participation expressed by patient.

Where it's running

• Ho Chi Minh City Hospital of Dermatology and Venereology
  Hanoi, Vietnam Recruiting
• Le Van Thinh Hospital
  Ho Chi Minh City, Vietnam Recruiting
• Bach Mai Hospital
  Hanoi, Vietnam Not yet recruiting

Study contacts

• Study coordinator: Dr. Nguyen Thi Phan Thuy, Doctor
• Email: devesh.kumar@innovate-research.com
• Phone: +91-9971169602

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Skincare regimen for mild to moderate acne in people with sensitive skin

  A 4-week test will check if a skincare regimen helps with mild to moderate acne in adults with sensitive skin.

  Recruiting USMARI Research & Innovation Centre · Petaling Jaya, Selangor · NCT07749469

• Engineered Lactobacillus reuteri cream with zinc sulfate–tannic acid MPN coating for acne

  This trial will test whether a topical cream containing engineered Lactobacillus reuteri with a zinc sulfate–tannic acid coating can reduce inflammatory acne in adults aged 18–33.

  Recruiting Phase 2 Shenzhen People's Hospital · Shenzhen, Guangdong · NCT07366229

• Probiotic drink for skin inflammation during the menopausal transition

  This study will test whether a daily Lactobacillus casei Shirota probiotic drink can reduce inflammation and improve immune and skin health in women aged 40–60 going through the menopausal transition with inflammatory facial skin conditions.

  Recruiting King's College London · London, London · NCT07341087

• Acne mRNA vaccine for adults with mild facial acne

  This trial will test two injections of an acne mRNA vaccine versus placebo in adults 18–45 with mild facial acne to see if it's safe, triggers an immune response, and improves acne.

  Recruiting at 4 sites Phase 1/2 Sanofi · Encino, California and 3 other locations · NCT07013747

• Evaluating the safety and effects of TVB-3567 in healthy individuals and those with acne

  This study is testing a new drug called TVB-3567 to see how safe it is and how it works in healthy people and those with acne.

  Recruiting at 3 sites Phase 1 Sagimet Biosciences Inc. · Tempe, Arizona and 5 other locations · NCT06989840

• Treatment for various skin conditions using AVAVA technology

  This study is testing a new device called AVAVA to see if it can help improve skin problems like acne, scars, and wrinkles.

  Recruiting AVAVA, Inc. · Waltham, Massachusetts · NCT06868615

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.